SPY240725P547000
- 8.49
- +3.14+58.69%
SPDR S&P 500 ETF Newsroom
Options Market Statistics: Ford Shares Plunge to Worst Day Since 2008 After Disappointing Earnings
Meta and Google admit that they may have invested too much in AI, but the risk of insufficient investment is far greater than that of excessive investment.
Technology giants would rather over-invest than invest too little, because in the technology industry, falling behind means having nothing at all.
Wednesday's Stock Market Pullback Was Painful. Here's What To Do Next
The 'bearish' that looms over the US stock market: expectations for 'understanding king' tariff increases.
According to Schroeder from Evercore, the US fiscal policy is unsustainable and the outcome may be very ugly. Trump's tariffs and immigration plans may trigger a trade war.
The Nasdaq fell nearly 1%, while small cap stock index rose over 1%. Nvidia turned higher after falling about 7%, and silver saw its deepest decline at 5%.
Continuously updating... Investors continue to sell technology stocks and buy blue chip and small cap stocks. The S&P 500 has fallen for three consecutive days, and the chip stock index opened low and fell by half. The Dow Jones and Russell small cap stock index rose throughout the day, and Tesla rose by as much as 4.6%. After rising 0.7%, the China concept stock index turned to a 0.7% decline. New Oriental fell 5.5% after Dong Yuhui resigned, while Xiaopeng and Li Auto rose nearly 2%. The European stock of French luxury goods giant Kering Group's Yoox Net-a-Porter fell more than 7% to a seven-year low. US bond prices rose and fell, leading the global bond market before the release of positive US second quarter GDP data. Offshore RMB surged more than 600 points on Thursday and rose more than 0.7% for three consecutive days, while the yen rose as much as 1% to a two-and-a-half-month high. Ethereum futures fell more than 6.7% on the third day of ETF listing, and London copper fell below $9,000 per ton for the f
This DB Chart Shows How the Tech Selloff Is Driving Moves Throughout the Stock Market
Serve Robotics Stock Continues To Soar: What's Going On?
These ETFs Let You Invest Based on Political Leanings - but Taking a Stance Can Be Costly
Bullish Sentiment Sees Biggest One-week Drop Since Feb 2023 in Latest AAII Survey
Nvidia, Alphabet, Microsoft, Drag S&P, Nasdaq Lower | Wall Street Today
6 days of consecutive sales! Berkshire Hathaway has a record amount of cash in hand, but remains steadfast in its shareholding of beloved Bank of America.
Some analysts believe that Buffett's shareholding reduction in Bank of America may be related to concerns about valuation. The current price of Bank of America has been getting closer to the level before the plunge of the US stock market in early 2022. In addition, tax rates may also be a possible reason. Regardless of the reason, based on Buffett's style, once the shareholding reduction starts, it will last for a considerable period of time.
Novo Nordisk Shares Decline Amid Competitive Pressure
Investors Go All In On Small Caps, Pour Over $6 Billion Into Russell 2000 ETF This Month: They 'Will Return To Larger-Cap Alternatives,' Veteran Analyst Says
Fed, FDIC, OCC Seek More Information From Banks on Bank-fintech Arrangements
Dow Leads Indexes Higher; GDP Beats Expectations
Express News | Manhattan DA Says Trump's Hush Money Conviction Should Stand; SCOTUS Ruling Has No Impact On Case
What's Going On With Tech Giant Meta's Stock Today?
Ford Options Volume Jump as Stock Heads for Worst Slump Since 2008
Alphabet Stock Falls As OpenAI Plans 'SearchGPT': What Investors Need To Know
Is the weight loss drug industry about to change? Viking Therapeutics rose nearly 40% intraday and hit a two-month high.
After communicating with the regulatory institution FDA, USA's Viking Therapeutics is pushing forward the weight-loss candidate drug VK2735 to phase III clinical trials ahead of schedule, potentially bringing the launch time forward by one year. This drug is expected to be injected once a month, which is more convenient than the same miraculous drug from Eli Lilly and Co and Novo Nordisk A/S. The oral version of VK2735 will start mid-term trials in the fourth quarter of this year.